Abstract: Described is a method of managing the bonding of transmissions over a legacy transmission system and over a new transmission system, the legacy transmission system comprising a legacy Cable Modem Termination System (CMTS), the new transmission system comprising a new CMTS and configured to transmit data using a new mode, the method comprising: receiving data at the new CMTS, the data comprising an identification of a receiver as a destination for the data, the legacy receiver configured to receive data transmitted using the legacy mode; monitoring an output of the legacy CMTS; and determining, based on the monitored output, whether to route the data to the legacy CMTS to transmit to the receiver.

Abstract: Methods and devices are described for managing the use of system resources in a wireless network. In one aspect, a method is performed by a wireless network system associated with a wireless network. The method provides upstream communications from an electronic device to the wireless network. The method includes: identifying a set of carriers that may be used together without causing an intermodulation product that falls within one or more active pass-bands associated with a receiver of the electronic device; and scheduling a carrier aggregated upstream communication from the electronic device to the wireless network using the identified set of carriers, the carrier aggregated upstream communication being an orthogonal frequency division multiplexing communication.

Abstract: Described are methods and devices for detecting cable network interference on a wireless network. In one aspect, disclosed is a method, performed by a processor of a cable interference detection device, of detecting interference in a wireless network caused by a cable network. The method includes: obtaining a signal signature of a wireless signal received at a receiver of a mobile communication device, the signal signature being a fast fourier transform representation of the wireless signal; and determining that the wireless signal represents interference caused by the cable network by comparing the signal signature to a cable network signal signature.

Abstract: Described are methods and devices for detecting cable network interference on a wireless network. In one aspect, disclosed is a method, performed by a processor of a cable interference detection device, of detecting interference in a wireless network caused by a cable network. The method includes: obtaining a signal signature of a wireless signal received at a receiver of a mobile communication device, the signal signature being a fast fourier transform representation of the wireless signal; and determining that the wireless signal represents interference caused by the cable network by comparing the signal signature to a cable network signal signature.

Abstract: Disclosed are methods and system for managing transmission of data between a hub and a receiver, the hub connected to the receiver by a first transport medium, and the hub connected to the receiver by a wireless network, the method comprising receiving a request from the receiver to transmit data upstream; determining that the data transmission across the first transport medium is congested; and, in response to determining that the data transmission across the first transport medium congested, instructing the receiver to transmit data upstream on the wireless network.

Abstract: Described is a method of managing the bonding of transmissions over a legacy transmission system and over a new transmission system, the legacy transmission system comprising a legacy Cable Modem Termination System (CMTS), the new transmission system comprising a new CMTS and configured to transmit data using a new mode, the method comprising: receiving data at the new CMTS, the data comprising an identification of a receiver as a destination for the data, the legacy receiver configured to receive data transmitted using the legacy mode; monitoring an output of the legacy CMTS; and determining, based on the monitored output, whether to route the data to the legacy CMTS to transmit to the receiver.

Abstract: Methods and devices are described for managing the use of system resources in a wireless network. In one aspect, a method is performed by a wireless network system associated with a wireless network. The method provides upstream communications from an electronic device to the wireless network. The method includes: identifying a set of carriers that may be used together without causing an intermodulation product that falls within one or more active pass-bands associated with a receiver of the electronic device; and scheduling a carrier aggregated upstream communication from the electronic device to the wireless network using the identified set of carriers, the carrier aggregated upstream communication being an orthogonal frequency division multiplexing communication.

Abstract: Compounds of Formula I are provided, as are methods for their preparation. The variables Z1, Z2, Z3, R4, R5, R6, R7, R8 and Ar in the above formula are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).

Abstract: Disclosed are compounds of the formula and the pharmaceutically acceptable salts thereof wherein R, Ar, A, n, R1 and R2 are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are also disclosed.

Abstract: Compounds of Formula (I) are provided, as are methods for their preparation. The variables W, X, Y, Z, R5, R8 and Ar in the above formula are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptorsin vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).

Abstract: Disclosed are compounds of the formula and the pharmaceutically acceptable salts thereof wherein R, Ar, A, n, R1 and R2 are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are also disclosed.

Abstract: Compounds of Formula I are provided, as are methods for their preparation. The variables Z1, Z2, Z3, R4, R5, R6, R7, R8 and Ar in the above formula are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).

Abstract: The invention provides Aryl substituted imidazoles, pyrazoles, pyridizines and related compounds of the Formula where the ring system represented by is a 5 membered heteroaryl ring system, in which x is 0, A is chosen from carbon and heteroatoms nitrogen, oxygen, and sulfur, and E and G are independently carbon or nitrogen provided that the 5 membered heteroaryl ring system does not contain more than 3 heteroatoms or more than 1 oxygen or sulfur atom, or a 6 membered heteroaryl ring system, in which x is 1, A, B, E, and G are independently chosen from carbon and nitrogen, provided that the 6 membered heteroaryl ring system does not contain more than 3 nitrogen atoms. The remaining variables, Ar1, Ar2, R, R1, R2, R3, R4, R5, R6, y and z are defined herein Such compounds are ligands of C5a receptors. Preferred compounds of the invention act bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors.

Abstract: Compounds of Formula I are provided. In which the variables are as described herein. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays.

Abstract: (Heterocycloalkyl)methyl azole derivatives of Formula (I) are provided: Formula I wherein A is oxygen, sulfur, or NR; J and K and each L are independently oxygen, sulfur, NH, or CH2; and the remaining variables are defined herein. Such compounds are modulators of C5a receptors, and preferably bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. Also provided herein are pharmaceutical compositions comprising such compounds, as well as methods for using such compounds in treating a variety of inflammatory and immune system disorders.

Abstract: Disclosed are compounds of formula (I) or pharmaceutically acceptable non-toxic salts or pharmaceutically acceptable solvates thereof wherein: (II) represents (a), (b), (c) or (d) and W, X, Y, A, B, C, D, E are variables as described herein. These compounds are highly selective agonists or antagonists at NK3 receptors or prodrugs thereof. The novel tachykinin NK-3 receptor antagonists contained in this invention have potential utility in the treatment of a broad array of disorders and diseases of the central nervous system (CNS) and periphery in mammals in which activation of NK-3 receptors is of importance.

Abstract: Disclosed is a tool having an axial passage, a top and a bottom, and a sidewall portion possessing porosity and permeability properties and constructed of a material having equal or better erosion properties than any substances produced and/or injected into any earth formation, said tool functioning as a filter to permit solids to pass or not pass depending upon their size, characterized in that the porosity and permeability can be programmed to any given value radially and longitudinally, said tool further including a means for circulating from outside, inward or from the inside outward to enable cleaning, wherein optionally said tool can be used in multiples.

Abstract: Disclosed are compounds of the formula: or pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, wherein R1, R2, R3, X, Q1 and Q2 are defined herein, which compounds are ligands for neurokinin receptors, in particular NK-3 receptors, and are therefor useful in the treatment of a wide range of diseases or disorders including, but not limited to depression, anxiety, psychosis, obesity, pain, Parkinson's disease, Alzheimer's disease, neurodegenerative diseases, movement disorders, respiratory diseases, inflammatory diseases, neuropathy, immune disorders, migraine, biliary disfunction, and dermatitis.

Abstract: Disclosed are compounds of formula (I) or pharmaceutically acceptable non-toxic salts or pharmaceutically acceptable solvates thereof wherein: (II) represents (a), (b), (c) or (d) and W, X, Y, A, B, C, D, E are variables as described herein. These compounds are highly selective agonists or antagonists at NK3 receptors or prodrugs thereof. The novel tachykinin NK-3 receptor antagonists contained in this invention have potential utility in the treatment of a broad array of disorders and diseases of the central nervous system (CNS) and periphery in mammals in which activation of NK-3 receptors is of importance.

Abstract: Substituted imidazole derivatives that bind to GABAA receptors are provided. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).